Levosimendan Bioglan (Levosimendan)

Levosimendan works by binding to troponin C, which sensitizes the heart muscle to calcium and strengthens each contraction without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in blood‑vessel walls, causing vasodilation and lowering the workload on the heart.

The dose of Levosimendan Bioglan is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The medication is administered intravenously under medical supervision, and dosing regimens are individualized for each patient.

Safety data for Levosimendan in pregnancy and lactation are limited. It is classified as having an unknown pregnancy category, and use is generally avoided unless the potential benefit justifies the risk to the mother and fetus. Breastfeeding mothers should consult their healthcare provider.

To order Levosimendan Bioglan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Levosimendan differs from traditional catecholamine inotropes such as dobutamine because it increases contractility without raising intracellular calcium, reducing the risk of calcium‑mediated toxicity. Its vasodilatory effect also lowers afterload, whereas many other inotropes primarily increase heart rate and may cause more pronounced tachyarrhythmias.

Levosimendan solution for injection should be stored at 2‑8 °C, protected from light, and kept in its original container. It must not be frozen or shaken. During handling, avoid exposure to temperatures above the recommended range and ensure aseptic techniques are used for preparation and administration.

Levosimendan is given as an intravenous infusion. The medication is typically diluted in a compatible solution and administered over a prescribed period under continuous cardiac and hemodynamic monitoring to ensure safety and therapeutic effectiveness.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare anaphylactic reactions. Patients should be closely monitored for blood pressure drops, abnormal heart rhythms, and any signs of chest pain or allergic response throughout the infusion and afterwards.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension unresponsive to treatment, and individuals with significant ventricular arrhythmias. Caution is also advised in patients with severe hepatic impairment or uncontrolled hypertension.